Articles by tag: lung-cancer

SBS5 and SBS18 Signatures: Oxidative Mutations from Smoking

Whole-exome sequencing revealed SBS5 and SBS18 mutations in smokers' cells. Learn about irreversible changes, lung cancer risk, and new diagnostic tests. Read details.

Mechanism of lung cell adaptation to tobacco smoke: the role of NRF2

Nature study: chronic smoke exposure causes mitochondrial fragmentation and NRF2 activation. How does this lead to cancer and why are antioxidants dangerous? Read.

New drug combination for lung cancer therapy: European approval

European Commission approved Zepzelca and atezolizumab combination for aggressive lung cancer. 27% reduction in risk of death. Learn details about the new standard of therapy.

ADC drugs against resistant small cell lung cancer: breakthrough 2026

New class of ADC drugs targets DLL3 and B7-H3, overcoming SCLC resistance. Analysis of efficacy, toxicity, and treatment prospects. Read more.

Orphan status of combination for lung cancer treatment: new EMA approach

European Commission granted orphan status to Zepzelca combination with atezolizumab for lung cancer. Learn how EMA reform changes rules for SCLC and who benefits from this decision. Detailed analysis.

Lung cancer drug Lurbinectedin approved in Europe

Europe approved the world's first Lurbinectedin drug with immunotherapy for aggressive lung cancer. 46% reduction in risk of death. Learn about the breakthrough and forecasts.

Tarlatamab (Imdelltra) approved by FDA: new standard for small cell lung cancer

FDA fully approved tarlatamab for second-line therapy of small cell lung cancer after the DeLLphi-304 study. Learn about the breakthrough in treatment and new options for patients.

ASCO 2026: biomarkers of response to Reqorsa gene therapy for lung cancer

Reqorsa gene therapy identified TROP2 and PTEN biomarkers for lung cancer prognosis. Learn ASCO 2026 data and prospects for treating NSCLC and SCLC.